These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7785970)

  • 41. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
    Emary WB; Toren PC; Mathews B; Huh K
    Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural basis of rifampin inactivation by rifampin phosphotransferase.
    Qi X; Lin W; Ma M; Wang C; He Y; He N; Gao J; Zhou H; Xiao Y; Wang Y; Zhang P
    Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3803-8. PubMed ID: 27001859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays.
    Troesch A; Nguyen H; Miyada CG; Desvarenne S; Gingeras TR; Kaplan PM; Cros P; Mabilat C
    J Clin Microbiol; 1999 Jan; 37(1):49-55. PubMed ID: 9854063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the bactericidal activity of a series of rifampicins against Mycobacterium leprae.
    Pattyn SR
    Arzneimittelforschung; 1982; 32(1):15-7. PubMed ID: 7037013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of rifampin-resistance in pathogenic mycobacteria.
    Williams DL; Waguespack C; Eisenach K; Crawford JT; Portaels F; Salfinger M; Nolan CM; Abe C; Sticht-Groh V; Gillis TP
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2380-6. PubMed ID: 7840574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.
    Weinstein ZB; Zaman MH
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Absorption, distribution, metabolism and excretion of rifampicin (3-(4-methyl-1-piperazinyl-iminomethyl) rifamycin SV) in the rat].
    Akimoto T; Ono K; Nanpo T
    Jpn J Antibiot; 1970 Jun; 23(3):250-6. PubMed ID: 5312377
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of rifampicin derivatives on the ion compartmentation of biological membranes.
    Inouye B; Uchinomi Y; Wachi T; Utsumi K
    J Antibiot (Tokyo); 1977 Jun; 30(6):494-9. PubMed ID: 885810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro susceptibility of atypical mycobacteria to rifampin.
    Molavi A; Weinstein L
    Appl Microbiol; 1971 Jul; 22(1):23-5. PubMed ID: 5111305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of rifampicin with nonprotein thiols in mycobacterium smegmatis.
    Kumar S; Ganguly NK; Kohli KK
    Biochem Int; 1991 Apr; 23(6):1041-7. PubMed ID: 1953799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene chip array for differentiation of mycobacterial species and detection of drug resistance.
    Shi XC; Liu XQ; Xie XL; Xu YC; Zhao ZX
    Chin Med J (Engl); 2012 Sep; 125(18):3292-7. PubMed ID: 22964326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rifamycin SV (Rifocin 500) clearance as a hepatic function test.
    Laudano OM; Brasca A
    Farmaco Prat; 1974 Jun; 29(6):347-50. PubMed ID: 4840110
    [No Abstract]   [Full Text] [Related]  

  • 53. New derivatives of rifamycin SV.
    Maggi N; Pallanza R; Sensi P
    Antimicrob Agents Chemother (Bethesda); 1965; 5():765-9. PubMed ID: 4956802
    [No Abstract]   [Full Text] [Related]  

  • 54. Determination of in vitro susceptibility of mycobacteria to ansamycin.
    Heifets LB; Iseman MD
    Am Rev Respir Dis; 1985 Sep; 132(3):710-1. PubMed ID: 3929660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacokinetics and biotransformation of rifamycins in the body of experimental animals].
    Subbotina NA; Griaznova NS; Beliavskaia IV; Sazykin IuO; Navashin SM
    Antibiotiki; 1979 Aug; 24(8):590-7. PubMed ID: 485106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Species-Specific Interactions of Arr with RplK Mediate Stringent Response in Bacteria.
    Agrawal P; Varada R; Sah S; Bhattacharyya S; Varshney U
    J Bacteriol; 2018 Mar; 200(6):. PubMed ID: 29311276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifampicin inactivation by Bacillus species.
    Dabbs ER; Yazawa K; Tanaka Y; Mikami Y; Miyaji M; Andersen SJ; Morisaki N; Iwasaki S; Shida O; Takagi H
    J Antibiot (Tokyo); 1995 Aug; 48(8):815-9. PubMed ID: 7592026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and metabolic studies with labeled rifamycin antibiotics.
    Keberle H; Meyer-Brunot H; Schmid K
    Antimicrob Agents Chemother (Bethesda); 1966; 6():365-70. PubMed ID: 5985259
    [No Abstract]   [Full Text] [Related]  

  • 59. Routine rapid Mycobacterium species assignment based on species-specific allelic variation in the 65-kilodalton heat shock protein gene (hsp65).
    Pai S; Esen N; Pan X; Musser JM
    Arch Pathol Lab Med; 1997 Aug; 121(8):859-64. PubMed ID: 9278615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis.
    Dhopie AM; Dhople AA; Ibanez MA
    Int J Antimicrob Agents; 1997; 8(3):209-14. PubMed ID: 18611804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.